• SELECT SITE CURRENCY
Select a currency for use throughout the site
New Approaches to the Treatment of Non-Hodgkin's Lymphoma
Decision Resources, Inc, December 2006, Pages: 24
Non-Hodgkin’s lymphoma, consisting of 29 different malignancies of the lymphatic system, is a devastating disease: although treatable, only a small percentage of these cancers are curable, and median survival of aggressive NHLs is poor. While treatment has greatly improved since the introduction of Genentech’s Rituxan in 1997, considerable unmet treatment needs remain, spurring significant development in NHL therapies.
Get the Answers You Need to Shape Your Strategy
Genentech’s Rituxan has generated strong growth in the NHL market since its launch, although Rituxan’s market penetration may have peaked. What factors will drive future growth in the NHL market? Where do opportunities lie in the treatment of NHL? How will emerging agents stack up against Rituxan?
With the launch of new agents, cost will become a driving factor in NHL treatment. Which emerging therapies or drug classes will command the highest prices in the NHL market? How will third-party payers respond to the arrival of potent but potentially expensive NHL therapies?
As many as 20 new therapies are in development for the treatment of NHL. Where will new therapies that arrive on the market fit alongside existing treatment regimens for NHL? What types of NHL will benefit most from new therapies? How will these agents be positioned in the market? What present agents, if any, will face competition?
Overview of non-Hodgkin’s lymphoma: disease characteristics, risk factors, classification and staging, and diagnosis and prevalence.
Lymphomas covered: follicular lymphoma, B-cell lymphomas, T-cell lymphomas, mantle cell lymphoma.
Current therapies: overview of agents currently in use to treat NHL.
Emerging therapies: a review of leading agents in development for NHL.
Drug classes covered: novel chemotherapy agents, combination therapies, vaccines, monoclonal antibodies, radioimmunotherapies.
Market outlook: our projections for how emerging agents could alter the NHL landscape.
Executive Summary 3
Strategic Considerations 3
Stakeholder Implications 3
Overview of Non-Hodgkin’s Lymphoma 4
Disease Characteristics and Risk Factors 4
Disease Classification, Staging, and Grade 6
Diagnosis and Prevalent and Incident Cases 8
Current Therapies 9
Emerging Therapies 13
Novel Chemotherapy Agents 13
Hana Bioscience’s Marquibo 13
Cephalon’s Treanda 13
Agents for Use in Combination with Rituxan 15
Genentech/Roche/Chugai’s Avastin 17
Immunomedics’ Epratuzumab 17
Biogen Idec’s Galiximab 18
Celgene’s Revlimid 18
Agents in Development for T-Cell Lymphomas 18
Gloucester Pharmaceuticals’ Romidepsin 18
Seattle Genetics’ SGN-30 19
Agents in Development for Mantle Cell Lymphoma 19
Wyeth’s Temsirolimus 19
Genta’s Genasense 19
Millennium Pharmaceuticals’ Velcade 19
Agents in Development for Relapsed or Refractory NHL 20
Genmab’s HuMax-CD20 20
Eli Lilly’s Enzastaurin 20
Other Agents in Development 21
Human Genome Sciences/GlaxoSmithKline’s Mapatumumab 21
Outlook for the NHL Market 21
1. Descriptions of Common Types of Non-Hodgkin’s Lymphomas 5
2. The WHO Classification System for Non-Hodgkin’s Lymphoma 7
3. Lymphoma Staging System: Ann Arbor Classification 8
4. Current Therapy Regimens for Non-Hodgkin’s Lymphoma 10
5. Select Agents in Development for Non-Hodgkin’s Lymphoma 14
1. Prevalent and Incident Cases of Non-Hodgkin’s Lymphoma, 2005 9
2. Number of Agents in Development by Strategy 22
Human Genome Sciences
Large Scale Biologics